Dataset related to the article "Peri-tumoural CD3+ Inflammation and Neutrophil-to-Lymphocyte Ratio Predict Overall Survival in Patients Affected by Colorectal Liver Metastases Treated with Surgery"

This record contains data related to article "Peri-tumoural CD3+ Inflammation and Neutrophil-to-Lymphocyte Ratio Predict Overall Survival in Patients Affected by Colorectal Liver Metastases Treated with Surgery" Background: Systemic and local inflammation plays an important role in many cancers and colorectal liver metastases (CRLM). While the role of local immune response mediated by CD3+ tumour-infiltrating lymphocytes is well-established, new evidence on systemic inflammation and cancer, such as neutrophil-lymphocyte ratio (NLR), is emerging. The aim of this study is to seek an association between the CD3+ lymphocytes and NLR with patients' prognosis and possibly stratifying it accordingly. Methods: From January 2005 to January 2013, 128 consecutive patients affected by CRLM and treated with chemotherapy and surgery were included in the study. Different cutoff levels were calculated with ROC curves for each of the biomarkers, and their relative outcome in terms of overall survival (OS) and recurrence-free survival (RFS) was determined. Associating the two biomarkers, three risk groups were determined: low risk (two protective biomarkers), intermediate risk (one protective biomarker) and high risk (no protective biomarker). Results: After a median follow-up of 45 months, median OS and RFS were 44 and 9 months, respectively. For OS, 29 (22.66%), 59 (46.09%) and 40 (31.25%) patients were in the low, intermediate and high-risk groups, respectively. Adjusted Cox regression analysis showed an increased risk of death in the intermediate group (HR 2.67 p = 0.007 95% CI 1.31-5.42) and high-risk group (HR 2.86 p = 0.005 95% CI 1.37-5.99) compared to the low-risk group (reference). Conclusion: Systemic and local immune response index allows stratification of patients in different OS and RFS risk groups.

本数据集包含与论文《肿瘤周围CD3+炎症状态与中性粒细胞-淋巴细胞比值可预测手术治疗结直肠癌肝转移患者的总生存期》相关的研究数据。
背景：系统性与局部炎症在多种癌症及结直肠癌肝转移（colorectal liver metastases, CRLM）中发挥关键作用。尽管CD3+肿瘤浸润淋巴细胞介导的局部免疫应答的作用已得到广泛证实，但关于系统性炎症与癌症的新证据正不断涌现，例如中性粒细胞-淋巴细胞比值（neutrophil-lymphocyte ratio, NLR）。本研究旨在探讨CD3+淋巴细胞与NLR和患者预后的关联，并据此对患者进行风险分层。
方法：2005年1月至2013年1月期间，本研究纳入128例连续入组的结直肠癌肝转移患者，所有患者均接受化疗联合手术治疗。通过受试者工作特征曲线（Receiver Operating Characteristic, ROC）计算各生物标志物的不同截断值，并明确其在总生存期（overall survival, OS）与无复发生存期（recurrence-free survival, RFS）方面的相对预后价值。结合两种生物标志物，可将患者划分为3个风险组别：低风险组（两种均为保护性生物标志物）、中风险组（仅一种为保护性生物标志物）及高风险组（无保护性生物标志物）。
结果：中位随访45个月后，患者的中位OS与中位RFS分别为44个月与9个月。低、中、高风险组的患者例数分别为29例（22.66%）、59例（46.09%）与40例（31.25%）。校正后的Cox回归分析显示，相较于作为参考组的低风险组，中风险组（风险比HR=2.67，P=0.007，95%置信区间CI：1.31~5.42）与高风险组（HR=2.86，P=0.005，95%置信区间CI：1.37~5.99）的死亡风险显著升高。
结论：系统性与局部免疫应答指标可将患者划分为不同OS与RFS风险组别。